

**THE ROLE OF CIRCULATING ENDOTOXAEMIA AS A
PROINFLAMMATORY MEDIATOR OF ATHEROSCLEROSIS IN
CHRONIC KIDNEY DISEASE PATIENTS**

Muzamil Olamide Hassan

A thesis submitted to the Faculty of Health Sciences, University of the Witwatersrand, in

fulfilment of the requirements for the degree

of

Doctor of Philosophy

Johannesburg, 2015

DECLARATION

I, Muzamil Olamide Hassan hereby declare that this thesis is original work done by me. It is being submitted for the degree of Doctor of Philosophy (Internal Medicine) in the University of the Witwatersrand, Johannesburg, South Africa. It has not been submitted previously for any degree or examination at this or any other University.

A handwritten signature in black ink, appearing to read 'Muzamil Olamide Hassan', with a horizontal line underneath.

22nd of June, 2015.

DEDICATION

I dedicate this work:

To my loving and supporting wife Mutiyat Adeyoola, my children, Sultan and Ahmad for
bearing with my long absence from home

To my parents, Alhaji Yunus Hassan and Alhaja Maryam Hassan for supporting me throughout
this journey

To almighty Allah, the most gracious and the most merciful

PUBLICATIONS AND PRESENTATIONS ARISING FROM THIS STUDY

A. Manuscript submitted for Publication

1. Assessment of volume overload and its risk factors in South African chronic kidney disease patients: an appraisal of bio-impedance spectroscopy and inferior vena cava diameter measurements – submitted to Nephrology, Dialysis and Transplantation (Appendix1)

B. Abstracts

1. Hassan M, Duarte R, Dix-Peek T, Vachiat A, Grinter S, Naidoo S, Manga P, Naicker S. Endotoxaemia: An independent risk factor for atherosclerosis in chronic kidney disease patients. (Abstract CS/TH-O-14). Wits Faculty of Health Science Research Day and Postgraduate Expo 2014 Abstract Book 2014 - published on line: South African Journal of Infectious Diseases, 2015; 30 (1): 4.
2. Hassan M, Duarte R, Dix-Peek T, Vachiat A, Grinter S, Naidoo S, Manga P, Naicker S. Immune activation contributes to severity of endotoxaemia related atherosclerosis in chronic kidney disease patients. World Congress of Nephrology, March 13th – 17th, 2015. Cape Town, South Africa. Abstract WCN15-1010, page 145, WCN 2015 Congress Program Book.
3. Hassan M, Duarte R, Dix-Peek T, Vachiat A, Grinter S, Naidoo S, Manga P, Naicker S. Correlation between volume overload, systemic inflammation and left ventricular dysfunction in chronic kidney disease patients: an appraisal of methods of hydration status assessment. World Congress of Nephrology, March 13th – 17th, 2015. Cape Town, South Africa. (Abstract WCN15-1012), page 345, WCN 2015 Congress Program Book.
4. Hassan M, Duarte R, Dix-Peek T, Vachiat A, Grinter S, Naidoo S, Manga P, Naicker S. Oxidized low density lipoprotein is an independent risk factor for cardiovascular disease in chronic kidney disease patients. World Congress of Nephrology, March 13th – 17th,

2015. Cape Town, South Africa. (Abstract WCN15-1013), page 345, WCN 2015 Congress Program Book.

5. Hassan M, Duarte R, Dix-Peek T, Naidoo S, Naicker S. The relationship between renal function, volume overload and circulating endotoxaemia in CKD patients. (Abstract NAN/CN/2015 – 10). In: Book of Abstracts, 27th Nigeria Association of Nephrology Congress, January 25th – 29th 2015, Calabar, Nigeria, p.35.
6. Hassan M, Duarte R, Dix-Peek T, Vachiat A, Grinter S, Naidoo S, Manga P, Naicker S. Circulating endotoxin is related to systemic inflammation and atherosclerosis in South African CKD patients. (Abstract NAN/CN/2015 – 12). In: Book of Abstracts, 27th Nigeria Association of Nephrology Congress, January 25th – 29th 2015, Calabar, Nigeria, p.37.

ABSTRACT

Atherosclerosis is increasingly recognized as a chronic inflammatory disease. Moreover, endotoxin release into the circulation is a potential source of inflammation, and represents an important target for intervention directed towards stemming of cardiovascular morbidity and mortality in chronic kidney disease (CKD) patients. Although previous studies have shown that elevated plasma endotoxin levels were associated with the risk of atherosclerosis, a direct link between endotoxaemia and atherosclerosis is yet to be fully elucidated. This study investigated endotoxaemia across the spectrum of South African CKD patients and also determined the pro-inflammatory effects of endotoxin that are relevant to the development of subclinical atherosclerosis in CKD patients.

A prospective cross-sectional study of 120 CKD patients was carried out, comprising 40 each of peritoneal dialysis (PD), haemodialysis (HD) and stage 3 chronic kidney disease (CKD), attending the Charlotte Maxeke Johannesburg Academic Hospital, South Africa; and a comparator cohort of 40 age- and sex-matched controls. Endotoxin levels were measured and the results compared with serum lipopolysaccharide binding protein (LBP), serum CD14 (sCD14), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1), oxidized LDL, interleukin-6 (IL-6), C-reactive protein (CRP), transforming growth factor- β (TGF- β), carotid intima media thickness (CIMT) and plaque occurrence (measured by B-mode ultrasound), and echocardiographic parameters. Bio-impedance spectroscopy was carried out using a body composition monitor (BCM) to assess fluid and nutritional status. Inflammatory cytokines including TGF- β 1 and IL-6 were genotyped, and the genotype frequencies compared to the serum concentrations of the cytokines. Data was analysed using the statistical package for social sciences (SPSS) version 16.

Volume overload and circulating endotoxaemia were common across the spectrum of CKD patients, and were aggravated by worsening kidney function. Endotoxins levels correlated

with both absolute overhydration ($r=0.513$, $p<0.001$) and percentage overhydration to extracellular water (OH/ECW%) ($r=0.490$, $p<0.001$). Carotid intima media thickness was significantly higher among CKD patients compared to the controls (0.58 ± 0.12 versus 0.45 ± 0.05 mm; $p<0.001$); CIMT was 0.63 ± 0.12 ; 0.56 ± 0.09 and 0.56 ± 0.12 mm in PD, HD and CKD stage 3 patients respectively. Carotid intima media thickness correlated with overhydration ($r=0.442$, $p<0.001$) and OH/ECW% ($r=0.421$, $p<0.001$). The risk of atherosclerosis was associated with serum levels of endotoxins (odds ratio: 2.34; confidence interval: 1.26-4.35, $p=0.007$), with excess risk confined to the group with high endotoxin levels. The risk of subclinical atherosclerosis was predicted by high concentrations of sCD14, IL-8 or MCP-1. Patients with high levels of circulating endotoxaemia in combination with high levels of sCD14, IL-8 or MCP-1 showed markedly elevated risk of atherosclerosis. The lowest Oxidized LDL levels were significantly higher in patients with carotid plaques compared to patients without carotid plaques (472.6 ± 104.6 versus 348.6 ± 110.9 ng/ml, $p=0.012$). Oxidized LDL showed a strong association with CIMT ($r=0.664$, $p<0.001$) among non-dialytic CKD patients. TGF- β isoforms were present in lower concentrations in haemodialysis patients compared to the PD, CKD and controls. TGF- β concentrations were significantly lower in the patients with subclinical atherosclerosis compared to patients without atherosclerosis (TGF- β 1: $4.1 \times 10^4 \pm 1.5 \times 10^4$ versus $5.9 \times 10^4 \pm 1.6 \times 10^4$ pg/ml, $p<0.001$; TGF- β 2: $1.6 \times 10^3 \pm 0.3 \times 10^3$ versus $1.8 \times 10^3 \pm 0.2 \times 10^3$ pg/ml, $p<0.001$; and TGF- β 3: $4.2 \times 10^2 \pm 0.9 \times 10^2$ versus $5.3 \times 10^2 \pm 1.1 \times 10^2$ pg/ml, $p<0.001$). TGF- β isoforms had an inverse relationship with CIMT (TGF- β 1: $r=-0.562$, $p<0.001$; TGF- β 2: $r=-0.477$, $p<0.001$; TGF- β 3: $r=-0.442$, $p<0.001$). There was significant association between IL6 polymorphisms (-174G/G and -174G/C) and elevated serum IL-6 levels in CKD patients.

Volume overload and circulating endotoxaemia were common across the spectrum of CKD patients. Volume overload was associated with the severity of kidney failure,

inflammation, malnutrition, atherosclerosis and cardiac enlargement. Bio-impedance spectroscopy device is a more sensitive tool than IVCD measurement for the assessment of fluid status in clinically euvolaemic non-dialytic stage 3 CKD patients. The findings suggest that the atherogenic predictive power of endotoxin is significantly increased by the presence of high concentrations of immune mediators in CKD patients. The increased risk of atherosclerosis in CKD patients was demonstrated to be due to the inflammation mediated by endotoxin, with protection afforded by TGB- β . Furthermore, there is a close association between IL-6 polymorphisms (G/G and G/C) and elevated serum IL-6 levels in CKD patients.

ACKNOWLEDGEMENTS

I wish to extend my sincere appreciation to:

- Professor Saraladevi Naicker my supervisor, for her guidance, initiative, encouragement and all round support.
- Dr Raquel Duarte the co-supervisor for her support, encouragement and valuable input and advice and for permitting the use of the Department of Internal Medicine Research Laboratory facilities.
- Dr Sagren Naidoo my host mentor and co-supervisor, for his assistance and support.
- Professor P Manga, Dr Ahmed Vachiat, Sacha Grinter of the Division of Cardiology of the Charlotte Maxeke Johannesburg Academic Hospital for assisting with the echocardiography and for allowing me to use the B-mode ultrasound machine for carotid artery intima media thickness measurement.
- Ms Therese Dix-Peek for her assistance in processing of my samples, and the many long hours she spent in helping run the ELISA assays.
- Dr Caroline Dickens for her assistance with all the genotyping assays and for assisting with the statistical analysis.
- Professor Graham Paget, consultants, fellows, Nurses and other staff of the Division of Nephrology CMJAH for their support and assistance during the course of my stay.
- Fresenius Medical Care, South Africa, for donating the Body Composition Monitor machine used to assess fluid and nutritional status of the study participants.
- The Department of Medicine and Division of Nephrology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg for providing funds for the purchase of some kits.
- The Faculty of Health Sciences Individual Research Grant.
- The National Research Fund for providing part funding for this research.

- AstraZeneca Research Trust for providing funding for genotyping assays.
- The International Society of Nephrology (ISN) for the fellowship award, which enabled me to study at the University of the Witwatersrand.
- The patients and the controls, for voluntarily participating in this study.

TABLE OF CONTENTS	Page
DECLARATION	ii
DEDICATION	iii
PUBLICATION AND PRESENTATIONS	iv
ABSTRACT	vi
ACKNOWLEDGEMENTS	ix
TABLE OF CONTENTS	xi
LIST OF FIGURES	xviii
LIST OF TABLES	xxii
LIST OF ABBREVIATIONS	xxiii
1.0 INTRODUCTION AND LITERATURE REVIEW	1
1.1 Epidemiology of CVD in CKD	3
1.2 Spectrum of Cardiovascular Pathology in Patients with Chronic Kidney Disease	4
1.2.1 Arterial Disease	4
1.2.2 Cardiac Disease	5
1.3 Overview of Risk Factors for Atherosclerotic cardiovascular disease in chronic kidney disease	5
1.3.1 Traditional risk factors	7
1.3.1.1 Hypertension	7
1.3.1.2 Dyslipidaemia	8
1.3.1.3 Diabetes Mellitus	10
1.3.1.4 Cigarette smoking	11
1.3.1.5 Age	11
1.3.1.6 Gender	12

1.3.1.7 Physical activity	13
1.3.1.8 Left ventricular hypertrophy	14
1.3.1.9 Genetic susceptibility for cardiovascular disease	15
1.3.2 Non-traditional risk factors	17
1.3.2.1 Inflammation	17
1.3.2.2 High-sensitivity C-reactive protein (hsCRP)	18
1.3.2.3 Oxidative stress	20
1.3.2.4 Endothelial dysfunction	22
1.3.2.5 Hyperhomocysteinaemia	23
1.3.2.6 Adiponectin	24
1.3.2.7 Fibroblast growth factor 23	25
1.4 An overview of pathogenesis of atherosclerosis	25
1.5 Bacteria Endotoxins	27
1.6 Detection and quantitation of endotoxins (LPS)	28
1.7 Endotoxin and Vascular Dysfunction	28
1.8 Signaling by endotoxin	29
1.8.1 Activation of cellular signaling pathways	29
1.8.2 Lipopolysaccharide binding protein	29
1.8.3 CD14	30
1.8.4 The TLR signaling pathway	30
1.9 Pro-inflammatory effects of endotoxin	31
1.10 Potential therapeutic strategies for the reduction of inflammation	

through endotoxin reduction	32
1.11 Transforming growth factor β levels and atherosclerosis Disease	34
1.12 Circulating endotoxaemia, renal function, and volume status	34
1.13 Carotid intima media thickness as a surrogate marker for CVD	35
1.14 Measurement of inferior vena cava diameter	36
1.15 Bio-impedance spectroscopy	36
1.16 Rationale for the study	37
1.17 Aim of study	38
1.18 Objectives	38
2.0 MATERIALS AND METHODS	39
2.1 Study design and population	39
2.1.1 Sample size	39
2.1.2 Inclusion criteria	39
2.1.3 Exclusion criteria	40
2.1.4 Controls	40
2.2 Methods	40
2.2.1 Blood collection and processing	41
2.2.2 Bio-impedance spectroscopy analysis – assessment of fluid and nutritional status	42

2.2.3	Inferior vena cava diameter measurement	43
2.2.4	Echocardiography	43
2.2.5	Carotid intima media thickness	44
2.2.6	Measurement of serum endotoxin levels	45
2.2.7	C-reactive protein, IL-6, IL-8, sCD14 and MCP-1 assays	46
2.2.8	Measurement of lipopolysaccharide binding protein concentrations	46
2.2.9	Measurement of oxidized LDL concentrations	47
2.2.10	Measurement of transforming growth factor β 1, β 2, and β 3 concentrations	47
2.2.11	DNA extraction and cytokine genotyping	47
2.3	Data analysis	49
3.0	RESULTS	51
3.1	Demographic data	51
3.2	Primary kidney disease	51
3.3	Blood pressure and drug treatment	53
3.4	Clinical and laboratory parameters of the study population	53
3.5	Characteristics of study population	55
3.5.1	Fluid status	55
3.5.2	Inflammatory markers	55
3.5.3	Echocardiographic parameters	56

3.5.4	Subclinical atherosclerosis	56
3.6	Prevalence of fluid overload according to various assessment methods	61
3.7	Receiver operating characteristic (ROC) curve analysis of fluid status assessment	61
3.8	Characteristics of patients with fluid overload	65
3.9	Nutritional status of the CKD patients	67
3.10	Associations between fluid status and measured variables in CKD patients	68
3.11	Relationship between renal function, volume overload and endotoxaemia	75
3.12	Subclinical atherosclerosis, endotoxemia, and inflammatory markers	82
3.13	Markers of immune activation and oxidative stress	87
3.14	Associations between endotoxin levels, markers of immune activation and carotid intima media thickness	89
3.15	Effect of immune activation on risk of endotoxin-induced atherosclerosis	91
3.16	Associations between oxidized LDL, lipid profile and inflammatory markers	93
3.17	Associations between oxidized LDL and cardiovascular disease	95
3.18	Transforming growth factor-beta (TGF- β) isoforms in levels CKD in patients	99
3.19	Transforming growth factor- β 1 isoform and Atherosclerosis	103
3.20	Relationship between TGF- β , pro-inflammatory cytokines and cardiovascular risk factors	107

3.21	Inflammatory cytokine polymorphisms in chronic kidney disease patients	110
4.0	DISCUSSION	113
5.0	CONCLUSIONS AND RECOMMENDATIONS	132
	Limitations of this study	133
	Recommendations	134
	REFERENCES	136
	APPENDICES	179
	APPENDIX 1	179
	APPENDIX 2	210
	APPENDIX 3	211
	APPENDIX 4	217
	APPENDIX 5	221
	APPENDIX 6	231
	APPENDIX 7	238
	APPENDIX 8	244
	APPENDIX 9	252
	APPENDIX 10	257
	APPENDIX 11	263
	APPENDIX 12	267

LIST OF FIGURES

Figure	Page
1.1 The stages of development of an atherosclerotic plaque	26
1.2 Schematic of bacterial endotoxin	27
1.3 Pro-atherogenic interactions between endotoxin and vascular cells	31
2.1 Schematic drawing showing the anatomy and sites of carotid intima media thickness measurement	45
2.2 Genotype of two patients and control according to their TNF- α , TGF- β 1, IL-10, IL-6 and IFN- γ polymorphisms	49
3.1 The spectrum of primary kidney disease in the chronic kidney disease patients	52
3.2 Comparison of fluid status between patients on peritoneal dialysis, haemodialysis, chronic kidney disease (stage 3) and the controls	58
3.3 Comparison of endotoxin levels between patients on peritoneal dialysis (PD), haemodialysis (HD) and with chronic kidney disease (CKD) versus controls	59
3.4 Comparison of carotid intima media thickness between patients on peritoneal dialysis, haemodialysis, chronic kidney disease and control haemodialysis patients	60
3.5 Receiver operating characteristics (ROC) for inferior vena cava diameter study population to predict volume overload using body composition monitor measurements as positive test	62
3.6 Receiver operating characteristics (ROC) for collapsibility index to predict volume overload using Body composition monitor measurements as positive test	63
3.7 Receiver operating characteristic (ROC) analysis of oedema on examination compared to body composition monitor measurements as a positive	64
3.8 Relationship between OH/ECW% (fluid status) and interleukin-6 in CKD patients	70
3.9 Relationship between OH/ECW% (fluid status) and left ventricular mass index	

in CKD patients	71
3.10 Relationship between overhydration and carotid intima media thickness in CKD patients	72
3.11 Relationship between OH/ECW% (fluid status) and carotid intima media thickness in CKD patients	73
3.12 Comparison of hydration status between CKD and non-CKD patients	76
3.13 Comparison of endotoxin levels between CKD and non-CKD patients	77
3.14 Comparison of endotoxin levels between patient without fluid overload and those with fluid overload	78
3.15 Relationship between endotoxin levels and absolute overhydration	79
3.16 Comparison of post-haemodialysis endotoxin levels between patients that had intradialytic hypotension and those without hypotension	80
3.17 Comparison of post-haemodialysis endotoxin level between patients with low ultrafiltration volume and those with high ultrafiltration volume	81
3.18 Comparison of carotid intima media thickness between CKD patients with elevated endotoxin level and those with low endotoxin levels	83
3.19 Serum interleukin-6 levels in CKD patients with high CIMT compared to those with normal CIMT	84
3.20 Serum C-reactive protein levels in CKD patients with high CIMT compared	

	to those with normal CIMT	85
3.21	Comparison of endotoxin levels between patients with carotid plaque and those without carotid plaque	86
3.22	Relationship between CIMT and MCP-1	89
3.23	Relationship between CIMT and serum CD14	90
3.24	Relationship between oxidized LDL/LDL ratio and oxidized LDL	94
3.25	Comparison of oxidized LDL levels between CKD patients with early atherosclerosis and those without atherosclerosis	96
3.26	Comparison of oxidized levels between patients with carotid plaque and those without carotid plaque	97
3.27	Relationship between oxidized LDL and CIMT in CKD (stage 3) patients	98
3.28	Serum TGF- β 1, 2 & 3 in the CKD patients groups and the controls.	101
3.29	Comparison of serum TGF- β 1, 2 & 3 between CKD patients and controls	102
3.30	Comparison of serum TGF- β 1, 2 & 3 between patients with subclinical atherosclerosis and those without atherosclerosis	104
3.31	Comparison of serum TGF- β 1, 2 & 3 (C) between patients with carotid plaque and those without plaques	105
3.32	Relationship between TGF- β 1 and CIMT in CKD patients	106
3.33	Relationship between TGF- β 3 and LBP in CKD patients	108

LIST OF TABLES

Table	Page
1.1 Risk factors for cardiovascular disease in CKD	6
3.1 Demographic data of the study population	51
3.2 Clinical and Laboratory characteristics of the study population	54
3.3 Fluid status, inflammatory markers, nutrition status and echocardiographic parameters in the study population	57
3.4 Comparison between patients with fluid overload and normal fluid status	66
3.5 Pattern of left ventricular hypertrophy in chronic kidney disease patients	67
3.6 Correlation between fluid parameters, renal function, inflammation and atherosclerosis markers, nutrition status and cardiac size	69
3.7 Multiple linear regression analysis of determinants of volume overload	74
3.8 Multiple linear regression analysis of determinants of CIMT	87
3.9: Comparison of endotoxin, markers of immune activation and oxidized LDL between CKD patients and controls	88
3.10 Risk of early atherogenesis by IL-8, MCP-1 and serum CD14 levels	92
3.11 Concentrations of TGF- β isoforms in the sub-groups of chronic kidney patients and the controls	100
3.12 TNF α , TGF- β 1, IL-10, IL-6 and IFN- γ genotyping showing genotype distribution and frequency in CKD patients and controls	111
3.13 Producer status and TGF- β 1 in genotyped CKD patients	112
3.14 Producer status and serum IL-6 levels in genotyped CKD patients	112

LIST OF ABBREVIATIONS

ACEI	angiotensin converting enzyme inhibitor
ADMA	asymmetric dimethylarginine
ADPN	adiponectin
AGES	advanced glycation end products
ADPKD	adult polycystic kidney disease
Apo	apolipoprotein
apo(a)	apolipoprotein (a)
ARBs	angiotensin II receptor blockers
ARIC	atherosclerosis risk in Communities
ASCVD	atherosclerotic cardiovascular disease
BCM	body composition monitor
BMI	body mass index
BIS	bio-impedance spectroscopy
BP	blood pressure
BSA	body surface area
CABG	coronary artery by-pass graft
CAD	coronary artery disease
CHF	congestive heart failure
CIMT	carotid intima-media thickness
CKD	chronic kidney disease
CI	collapsibility index
CP	chronic pyelonephritis /reflux nephropathy
CRF	chronic renal failure
CRP	C-reactive protein

CVD	cardiovascular disease
DBP	diastolic blood pressure
DNA	deoxyribonucleic acid
Echo	echocardiography
ESRD	end-stage renal disease
FGF-23	fibroblast growth factor-23
GFR	glomerular filtration rate
GN	glomerulonephritis
GNB	gram negative bacilli
Hb	haemoglobin
HD	haemodialysis
HDL	high density lipoprotein
HMG-CoA	hydroxy methylglutaryl coenzyme A
Hs-CRP	high sensitivity C-reactive protein
HTN	hypertension
ICAM	soluble intercellular adhesion molecule 1
IDL	intermediate density lipoprotein
IHD	ischaemic heart disease
IL-2	interleukin-2
IL-6	interleukin-6
IL-8	interleukin-8
IMT	intima-media thickness
INF- γ	interferon- γ
IVCD	inferior vena cava diameter
IVSTd	interventricular wall thickness during diastole

KDIGO	Kidney Disease Improving Global Outcomes
LCAT	lecithin- cholesterol acyl-transferase
LDL	low density lipoprotein
LMW	low molecular weight
Lp	lipoprotein
Lp(a)	lipoprotein (a)
LPL	lipoprotein lipase
LPS	lipopolysaccharide
LBP	lipopolysaccharide binding protein
LVEDD	left ventricular internal dimension measurements in end-diastole
LVESD	left ventricular internal dimension measurements in end-systole
LVH	left ventricular hypertrophy
LVM	left ventricular mass
LVMi	left ventricular mass index
MABP	mean arterial blood pressure
MCP-1	monocyte chemoattractant protein-1
MI	myocardial infarction
NA	not available.
NHANES	National Health and Nutrition Examination Survey
NHLS	National Health Laboratory
NKF	National Kidney Foundation
NOS	nitric oxide synthase
NYHA	New York Heart Association
O ₂ ⁻	superoxide anion
oxLDL	oxidized low density lipoprotein

PD	peritoneal dialysis
PTH	parathyroid hormone
PWTd	posterior wall thickness during diastole
ROS	reactive oxygen species
RRT	renal replacement therapy
RWT	relative wall thickness
SBP	systolic blood pressure
SDMA `	symmetric dimethylarginine
SMC	smooth muscle cell
TG	triglyceride
TNF- α	tumour necrosis factor- α
TGF- β	transforming growth factor
TLR-4	toll-like receptor-4
USA	United States of America
USRDS	United States Renal Data System
VCAM-1	vascular adhesion molecule 1
VLDL	very- low- density- lipoprotein